Is Inovio Pharmaceuticals Stock a Buy?

Investing in clinical-stage biotech companies isn't for the faint of heart. Negative results from clinical trials or regulatory roadblocks can send shares of these companies plunging. On the other hand, investing in the right clinical-stage biotech stock can reap life-changing returns, particularly if the company in question develops a vaccine for an infectious disease that has spread across the world and has killed thousands of people.

One company that could go on to do just that is Inovio Pharmaceuticals (NASDAQ: INO). The biotech has been racing through the early stages of the development of its investigational coronavirus vaccine, INO-4800. As a result, Inovio's stock is up by 343.3% year to date as of this writing. Before pulling the trigger on this biotech stock, though, let's take a closer look at what's really going on with Inovio Pharmaceuticals.